Asian Markets More Important Than Their Pipelines - CLSA Hong Kong Investor Forum
This article was originally published in The Pink Sheet Daily
Executive Summary
If China chose to dominate the generics field, it could probably do it within 10 years, industry expert says.
You may also be interested in...
China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine
BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.